You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Scanfil Q2’24: Topline problems, but attractive valuation
Weak demand and customer destocking – revenue down by almost 20% year-on-year. Given the magnitude of the revenue drop, the company's cost structure was very resilient. Analyst Antti Viljakainen summarizes.
00:00 Intro
00:11 Q2 result vs. profit warning
01:12 Reason behind sluggish figures
01:52 Cost reductions
02:33 Guidance & big picture
04:18 Segments
05:51 Valuation & recommendation
Read the latest research:
Scanfil Q2'24: No miracles needed for the price level
Read the Q2’24 result flash comment:
Good operating profitability on weak volumes
Aktier i Vælten - Novo Nordisk: Vi må vente på re-eksamen efter skuffende data
Introduction to the Helsinki Stock Exchange | Company Night Dec. 16, 2024
Surgical Science Sweden, Audiocast with teleconference, Press Conference, 2024
GomSpace – Management Q&A
ExpreS2ion Biotech – A look back at 2024 with CEO
Vis alle videoer